The global generic oncology sterile injectable market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 3.2 billion by 2030. The growth of this market is driven by factors such as increasing incidence of cancer and rising demand for cost-effective treatment options.
Chemotherapy drugs are the largest segment in the global generic oncology sterile injectable market, accounting for over 50% share in 2017 and are expected to continue their dominance throughout the forecast period. Chemotherapy drugs are used to treat various types of cancer such as leukemia, lymphoma, breast cancer, lung cancer and prostate cancer among others. Monoclonal antibodies segment is expected to grow at a CAGR of 6% during the forecast period due to their ability to target specific cells or proteins that cause disease or infection without harming healthy cells or tissues around them. Cytokines segment accounted for over 10% share in 2017 and are anticipated to grow at a CAGR of 7%. Peptide hormones accounted for less than 1% share in 2017 but are anticipated to grow at a CAGR of 8%.
Industry Growth Insights published a new data on “Generic Oncology Sterile Injectable Market”. The research report is titled “Generic Oncology Sterile Injectable Market research by Types (Chemotherapy, Monoclonal Antibodies, Cytokines, Peptide Hormones), By Applications (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Players/Companies Eli Lilly & Company, Biocon Ltd, Baxter International Inc, Hikma Pharmaceuticals PLC, Mylan N.V, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Pfizer Inc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Generic Oncology Sterile Injectable Market Research Report
By Type
Chemotherapy, Monoclonal Antibodies, Cytokines, Peptide Hormones
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Eli Lilly & Company, Biocon Ltd, Baxter International Inc, Hikma Pharmaceuticals PLC, Mylan N.V, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Pfizer Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Generic Oncology Sterile Injectable Market Report Segments:
The global Generic Oncology Sterile Injectable market is segmented on the basis of:
Types
Chemotherapy, Monoclonal Antibodies, Cytokines, Peptide Hormones
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly & Company
- Biocon Ltd
- Baxter International Inc
- Hikma Pharmaceuticals PLC
- Mylan N.V
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc
Highlights of The Generic Oncology Sterile Injectable Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Monoclonal Antibodies
- Cytokines
- Peptide Hormones
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Generic Oncology Sterile Injectable Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Generic oncology sterile injectable is a medication that is used to treat various types of cancer. It is available as a generic drug and can be found at many pharmacies.
Some of the key players operating in the generic oncology sterile injectable market are Eli Lilly & Company, Biocon Ltd, Baxter International Inc, Hikma Pharmaceuticals PLC, Mylan N.V, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Pfizer Inc.
The generic oncology sterile injectable market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Generic Oncology Sterile Injectable Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Generic Oncology Sterile Injectable Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Generic Oncology Sterile Injectable Market - Supply Chain
4.5. Global Generic Oncology Sterile Injectable Market Forecast
4.5.1. Generic Oncology Sterile Injectable Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Generic Oncology Sterile Injectable Market Size (000 Units) and Y-o-Y Growth
4.5.3. Generic Oncology Sterile Injectable Market Absolute $ Opportunity
5. Global Generic Oncology Sterile Injectable Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Generic Oncology Sterile Injectable Market Size and Volume Forecast by Type
5.3.1. Chemotherapy
5.3.2. Monoclonal Antibodies
5.3.3. Cytokines
5.3.4. Peptide Hormones
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Generic Oncology Sterile Injectable Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Generic Oncology Sterile Injectable Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Generic Oncology Sterile Injectable Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Generic Oncology Sterile Injectable Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Generic Oncology Sterile Injectable Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Generic Oncology Sterile Injectable Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Generic Oncology Sterile Injectable Demand Share Forecast, 2019-2026
9. North America Generic Oncology Sterile Injectable Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Generic Oncology Sterile Injectable Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Generic Oncology Sterile Injectable Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Generic Oncology Sterile Injectable Market Size and Volume Forecast by Type
9.7.1. Chemotherapy
9.7.2. Monoclonal Antibodies
9.7.3. Cytokines
9.7.4. Peptide Hormones
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Generic Oncology Sterile Injectable Demand Share Forecast, 2019-2026
10. Latin America Generic Oncology Sterile Injectable Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Generic Oncology Sterile Injectable Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Generic Oncology Sterile Injectable Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Generic Oncology Sterile Injectable Market Size and Volume Forecast by Type
10.7.1. Chemotherapy
10.7.2. Monoclonal Antibodies
10.7.3. Cytokines
10.7.4. Peptide Hormones
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Generic Oncology Sterile Injectable Demand Share Forecast, 2019-2026
11. Europe Generic Oncology Sterile Injectable Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Generic Oncology Sterile Injectable Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Generic Oncology Sterile Injectable Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Generic Oncology Sterile Injectable Market Size and Volume Forecast by Type
11.7.1. Chemotherapy
11.7.2. Monoclonal ntibodies
11.7.3. Cytokines
11.7.4. Peptide Hormones
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Generic Oncology Sterile Injectable Demand Share, 2019-2026
12. Asia Pacific Generic Oncology Sterile Injectable Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Generic Oncology Sterile Injectable Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Generic Oncology Sterile Injectable Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Generic Oncology Sterile Injectable Market Size and Volume Forecast by Type
12.7.1. Chemotherapy
12.7.2. Monoclonal Antibodies
12.7.3. Cytokines
12.7.4. Peptide Hormones
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Generic Oncology Sterile Injectable Demand Share, 2019-2026
13. Middle East & Africa Generic Oncology Sterile Injectable Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Generic Oncology Sterile Injectable Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Generic Oncology Sterile Injectable Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Generic Oncology Sterile Injectable Market Size and Volume Forecast by Type
13.7.1. Chemotherapy
13.7.2. Monoclonal Antibodies
13.7.3. Cytokines
13.7.4. Peptide Hormones
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Generic Oncology Sterile Injectable Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Generic Oncology Sterile Injectable Market: Market Share Analysis
14.2. Generic Oncology Sterile Injectable Distributors and Customers
14.3. Generic Oncology Sterile Injectable Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Eli Lilly & Company
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Biocon Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Baxter International Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Hikma Pharmaceuticals PLC
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Mylan N.V
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sandoz International GmbH
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Teva Pharmaceutical Industries Ltd.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Pfizer Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
